Table 1.
Proportion of individuals aged ≥ 15 years with viral load (VL) monitoring, and with optimal monitoring, during first 12 and 24 months on antiretroviral therapy (ART)
| Year of ART initiation | N starting ART | Median (IQR) age (years) | Female (%) | n with VL at 6 months/N on ART † (%) | n with VL at 12 months/N on ART ‡ (%) | n with VL at 24 months/N on ART § (%) | N (%) with optimal monitoring to 12 months ¶ | N (%) with optimal monitoring to 24 months # |
|---|---|---|---|---|---|---|---|---|
| 2010 | 3177 | 33 (27–41) | 67.5 | 1234/2495 (49.5%) | 869/2354 (36.9%) | 839/2150 (39.0%) | 361 (15.3%) | 217 (10.1%) |
| 2011 | 3543 | 34 (27–41) | 69.4 | 1544/2961 (52.1%) | 1021/2823 (36.2%) | 764/2597 (29.4%) | 381 (13.5%) | 153 (5.9%) |
| 2012 | 4040 | 33 (27–41) | 66.7 | 1495/3406 (43.9%) | 977/3235 (30.2%) | 865/2993 (28.9%) | 328 (10.1%) | 146 (4.9%) |
| 2013 | 3642 | 30 (25–38) | 71.1 | 907/2897 (31.3%) | 757/2741 (27.6%) | 750/2523 (29.7%) | 207 (7.6%) | 101 (4.0%) |
| 2014 | 3988 | 29 (24–37) | 73.3 | 793/3231 (24.5%) | 1017/3045 (33.4%) | 619/2740 (22.6%) | 252 (8.3%) | 87 (3.2%) |
| 2015 | 5556 | 31 (25–38) | 70.6 | 2035/4695 (43.3%) | 1391/4428 (31.4%) | 497/3962 (12.5%) | 519 (11.7%) | 88 (2.2%) |
| 2016 | 5438 | 31 (25–38) | 69.8 | 1853/4514 (41.1%) | 1733/4181 (41.4%) | – | 682 (16.3%) | – |
| Total | 29 384 | 31 (26–39) | 69.9 | 9861/24 199 (40.7%) | 7765/22 807 (34.0%) | 4334/16 965 (25.5%) | 2730 (12.0%) | 1054 (6.2%) |
Viral load measurement done between > 20 weeks and 9 months after starting ART. Denominator refers to individuals who have been on ART for at least 9 months.
Viral load measurement done between > 9 and 15 months after starting ART. Denominator refers to individuals who have been on ART for at least 15 months.
Viral load measurement done between > 21 and 27 months after starting ART. Denominator refers to individuals who have been on ART for at least 27 months.
Optimal monitoring during first 12 months is defined as a viral load measurement at 6 and 12 months after ART initiation, using the windows in footnotes † is > 20 weeks and 9 months and ‡ is > 9 months and 15 months. Denominator refers to individuals who have been on ART at least 15 months.
Optimal monitoring during the first 24m is defined as a viral load measurement at 6m, 12m and 24m after ART initiation, using windows in footnotes † is > 20 weeks and 9 months, ‡ is > 9 months and 15 months and § is > 21 months and 27 months. Denominator is individuals who have been on ART at least 27 months.